Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001437749-17-010129
Filing Date
2017-05-26
Accepted
2017-05-26 09:01:07
Documents
4
Period of Report
2017-07-07
Effectiveness Date
2017-05-26

Document Format Files

Seq Description Document Type Size
1 FORM DEF 14A atrn20170518_def14a.htm DEF 14A 525443
2 card3.jpg GRAPHIC 103692
3 card2.jpg GRAPHIC 371635
4 card1.jpg GRAPHIC 192010
  Complete submission text file 0001437749-17-010129.txt   1445911
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-51353 | Film No.: 17871902
SIC: 7389 Services-Business Services, NEC